×

Agilent Technologies: PD-L1 IHC 28-8 PharmDx Gets CE-IVD Mark Approval

Published Oct 21 2021 at 12:53 PM GMT
Key
Points
  • (A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
  • When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion.




Trending

Stats

  • Published Oct 21, 2021 12:53 PM GMT